Morgan Stanley Maintains Equal-Weight on Biogen, Lowers Price Target to $222

Benzinga Newsdesk www.benzinga.com Negative 48.2%

Neg 48.2% Neu 0% Pos 0%

Morgan Stanley analyst Matthew Harrison maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and lowers the price target from $224 to $222.